Engflag

Delator

Quick links to important sections

Delator

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Delator

Property Description
Active ingredient Atorvastatin
Form Film-coated tablets
Pharmacological class HMG-CoA reductase inhibitor (Statin)
General purpose Lipid profile management and cardiovascular risk reduction
Origin Synthetic compound

What is Delator and What Pharmacological Class Does it Belong To?

Delator is a synthetic, single-ingredient prescription drug used for the chronic management of elevated blood lipids. Its core identity is defined by its active chemical substance, Atorvastatin, and its pharmacological classification as an HMG-CoA reductase inhibitor. This classification identifies Delator as belonging to the drug group known as statins, a primary therapeutic category utilized in cardiovascular medicine. The designation as a statin means its action is specifically targeted toward the enzymatic pathways of cholesterol synthesis, fundamentally distinguishing it from other lipid-modifying agents. Pharmacological studies have clinically recognized statins as the first-line therapy for addressing hypercholesterolemia. The HMG-CoA reductase inhibitors are recognized as essential medicines for cardiovascular conditions.

Delator's Physical Form and Active Composition

Delator is supplied for oral administration exclusively in the form of film-coated tablets. The primary active component is the substance Atorvastatin, typically incorporated as the calcium trihydrate salt to ensure pharmaceutical stability and predictable systemic absorption. As a synthetic compound, it is a single-entity pharmaceutical product. Unlike some multi-ingredient preparations designed for complex metabolic issues, Delator focuses solely on the well-established action of Atorvastatin. This formulation is optimized for straightforward ingestion and subsequent dissolution within the digestive tract, facilitating the necessary long-term systemic effect required for managing chronic lipid disorders.

What is the General Purpose of Taking Delator?

The general purpose of taking Delator is to act as a lipid-modifying agent to improve a patient’s overall lipid profile. This action serves to correct persistent dyslipidemia, defined by the presence of abnormal concentrations of fats in the blood, such as high levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG). Atorvastatin is recognized for its efficacy in reducing total cholesterol and LDL-C in patients with primary hypercholesterolemia. By successfully reducing these elevated lipid levels, Delator supports the broad goal of mitigating the associated long-term cardiovascular risk by reducing fat accumulation in the arterial walls.

Regulatory References

  1. WHO Essential Medicines Lists

What side effects are possible with Delator?

Official Side Effects and Safety Information

The possible adverse reactions of Delator (Atorvastatin) are classified in regulatory documents by the frequency with which they are observed, ranging from common to very rare.

Adverse Reaction Scope

The most commonly documented adverse reactions in clinical trials include effects grouped under Infections and Infestations, such as nasopharyngitis, and those affecting the Nervous System (headache) and the Gastrointestinal system (e.g., diarrhea, constipation). Effects on the Musculoskeletal system, such as myalgia (muscle pain) and arthralgia (joint pain), are also frequently listed [Source: FDA Label].

Serious Adverse Reactions and Safety Focus

Official labeling highlights the potential for rare but serious adverse reactions, particularly those affecting the muscles and liver. These serious reactions include myopathy and rhabdomyolysis, which is a severe muscle breakdown that can lead to kidney complications. The risk of these muscle-related events is noted in regulatory text to increase with higher dosages and when used in combination with certain other medicines [Source: EMA SmPC].

Furthermore, the medication is associated with abnormalities in liver function tests, and, rarely, with hepatic failure. Warnings also exist for the potential for new-onset diabetes and documented reports of cognitive impairment (such as memory loss or confusion) associated with the statin class [Source: FDA Label].

Population-Specific Safety Constraints

Atorvastatin is contraindicated by official regulatory bodies in patients with active liver disease or unexplained persistent elevations in liver enzymes. It is also contraindicated during pregnancy and lactation, as stated in the prescribing information. Advanced age is listed as a predisposing factor for muscle-related adverse effects [Source: FDA Label].

Connection to the Official Safety Profile

The official safety information structures the medicine's risk profile by formally classifying all documented adverse reactions and emphasizing the need for monitoring of the musculoskeletal and hepatic systems. This framework establishes the constraints on use, particularly in individuals with pre-existing liver conditions or who are pregnant, thereby defining the established parameters for the safe regulatory use of the medication.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Delator (Atorvastatin)

The official regulatory profile for Delator focuses on managing the acute risk of severe toxicities rather than a distinct overdose syndrome. In case of overexposure, the primary concern is the potential for rhabdomyolysis (severe muscle breakdown) which can lead to acute kidney injury (renal failure), as well as the risk of serious hepatic injury. These outcomes are classified as life-threatening in official documentation.

Mandatory Actions and Clinical Manifestations

Regulators require the prompt reporting of specific manifestations that may indicate severe toxicity. These clinical signs include unexplained muscle pain, tenderness, or weakness, particularly if these symptoms are accompanied by malaise or fever. Upon suspicion or diagnosis of myopathy or serious hepatic injury, the drug must be promptly discontinued. Population-specific risks for these severe outcomes include advanced age (≥65 years) and existing renal impairment.

Management and Constraints

  • No specific antidote is documented for Delator overdosage in official labeling.
  • Treatment is limited to symptomatic and supportive measures instituted as required.
  • Hemodialysis is generally not expected to significantly enhance clearance. Continuous monitoring may be required for high-risk patients to manage the potential for renal complications.

Therapeutic Uses of Delator

Delator (Atorvastatin) is commonly used to address symptoms related to systemic imbalance, specifically the presence of abnormal concentrations of fats in the bloodstream, such as high Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. The medication plays a role in managing these abnormal concentrations, contributes to the management of the blood's lipid profile.

The primary therapeutic focus is on cardiovascular risk mitigation. It is considered relevant when supportive symptom management is appropriate for symptoms associated with acute or episodic changes, and may assist with mitigating future symptomatic risk.

“It is commonly used across conditions presenting with chronic, high-risk patterns where additional symptomatic support is needed.”

Delator is relevant for conditions including primary hypercholesterolemia, mixed dyslipidemia, and the Familial Hypercholesterolemia (HeFH and HoFH) in appropriate patient groups. This management assists with maintaining functional stability in contexts involving heightened systemic burden, especially for high-risk patients, including those with Type 2 Diabetes Mellitus.

Quick Fact: Relief for Asymptomatic Cardiovascular Strain Delator is primarily applied for long-term risk reduction and management of blood fat concentrations rather than acute physical discomfort, supports the patient during episodes of heightened cardiovascular risk exposure.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Delator (Atorvastatin) — Official Regulatory Information

Delator's eligibility profile is defined by governmental authorities to identify patient populations for whom the medicine is safe or prohibited.

Populations for whom use is allowed (as stated in label):

  • Adults (ge 18 years) for approved lipid-lowering uses.
  • Pediatric patients aged 10 years and older with specific types of familial hypercholesterolemia.

Populations for whom use is contraindicated:

  • Patients with active liver disease or persistent, unexplained elevations of serum transaminases exceeding three times the upper limit of normal (> 3 imes ULN).
  • Females who are pregnant, breastfeeding, or of childbearing potential and not using adequate contraception.
  • Patients with hypersensitivity to the active substance (Atorvastatin).

Age-related eligibility rules:

  • Pediatric Use: Use is generally not established or not recommended in children under 10 years of age.
  • Older Adults (ge 65 years): Fully eligible; however, advanced age is a risk factor for myopathy, requiring careful assessment.

Condition-specific eligibility rules:

  • Hepatic Impairment: Contraindicated in active liver disease. Use requires caution in patients with a history of liver disease or high alcohol consumption.
  • Muscle Risk: Patients with pre-existing risk factors for muscle damage, such as uncontrolled hypothyroidism or renal impairment, must be assessed carefully before and during treatment.

Official eligibility statements: Delator is contraindicated in patients with active liver disease or during pregnancy and lactation. Use is approved for adults and adolescents ge 10 years for specific conditions. Renal impairment and hypothyroidism are listed as predisposing risk factors for muscle toxicity, requiring cautious use. This structure outlines the mandatory regulatory boundaries for Delator's application.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Delator (Atorvastatin) interacts with co-administered substances primarily through effects on drug metabolism and transport, as documented in official regulatory labeling.

Contraindicated Combinations

Certain combinations are explicitly restricted due to the heightened risk of serious adverse muscle effects (myopathy and rhabdomyolysis), which is a key regulatory constraint. Co-administration with Cyclosporine, Tipranavir plus Ritonavir, and Glecaprevir plus Pibrentasvir is contraindicated or must be avoided.

Pharmacokinetic and Pharmacodynamic Interactions

Atorvastatin is a substrate for the CYP3A4 enzyme and drug transporters like OATP1B1, making its plasma concentrations susceptible to alteration. Potent CYP3A4 inhibitors (e.g., Clarithromycin) significantly increase atorvastatin exposure, often necessitating dosage restrictions. Conversely, Rifampin requires simultaneous co-administration to prevent a reduction in Delator's plasma concentrations.

Pharmacodynamic interactions involve an additive risk of myopathy with agents like Fibric Acid Derivatives (e.g., Gemfibrozil), Colchicine, and lipid-modifying doses of Niacin (1 g/day or more).

Drug–Substance Restrictions

Regulatory documents advise against the consumption of large amounts of Grapefruit Juice (1.2 liters or more daily) as it increases drug concentration. Similarly, St. John's Wort is noted to reduce Delator's plasma levels, potentially affecting efficacy. Patients with chronic alcoholic liver disease have markedly increased atorvastatin plasma concentrations, which may elevate the clinical relevance of these interactions.

Mechanism of Action

Direct Inhibition of Endogenous Cholesterol Production

Delator's primary mechanism involves its action as a competitive inhibitor of the enzyme HMG-CoA reductase, which controls the rate-limiting step in the Mevalonate pathway inside the liver. By blocking this enzyme, the drug reduces the rate of cholesterol synthesis, resulting in a shift in the intracellular cholesterol pool.

Upregulation of Hepatic LDL Clearance

The resulting shift in intracellular cholesterol triggers a strong physiological feedback mechanism: the significant upregulation of LDL receptors on the hepatocyte surface. This increase in receptor density enhances the scavenging and clearance of Low-Density Lipoprotein Cholesterol ( LDL-C) from the bloodstream, resulting in lower circulating plasma LDL-C concentrations.

Modulation of Vascular Endothelial Function

Beyond its core lipid-lowering action, the drug engages secondary pleiotropic effects by modulating signaling within the vascular endothelium. This action is associated with reduced localized inflammatory markers and improved bioavailability of nitric oxide, which modulates vascular tone and function.

Dosage and Administration Information

Instruction Map: How to use Delator — Administration Guidelines

Delator is an oral medication intended for long-term chronic management, administered exclusively as a film-coated tablet. Its use is structured as an adjunct to a cholesterol-lowering diet. The guidelines define the required dosage, schedule, and patient-specific rules for use.

Administration scope

Field Instruction
Route of administration: Oral administration.
Dosing schedule: The standard starting dose for adults is 10 mg or 20 mg once daily. The maintenance range is 10 mg to 80 mg once daily, with the maximum recommended daily dose being 80 mg.
Timing in relation to meals (if applicable): May be taken with or without food and at any time of the day.
Preparation requirements (if applicable): None stated for the film-coated tablet form.
Age-group administration rules: No dosage adjustment is required for patients with renal impairment or older adults. Specific ranges are defined for pediatric patients (10+ years) with HeFH.
Missed-dose rules: If a dose is missed, it is advised to skip the missed dose and resume the regular schedule; double-dosing is prohibited.
Special procedural conditions: Dosing must be restricted (e.g., 20 mg or 40 mg maximum) when co-administered with certain drug inhibitors. Consumption of large quantities of grapefruit juice (>1.2 liters per day) should be avoided.

Instruction classifications (high-level)

Field Classification
Administration method type: Oral
Frequency pattern: Daily (once daily)
Use-context constraints: Dose titration should occur at intervals of 4 weeks or more.

Resulting procedural structure

Step sequence:

  • The initial dose of Delator is selected from the starting range (e.g., 10 mg or 20 mg).
  • The drug is administered orally once daily, regardless of the time of day or meal consumption.
  • Efficacy is assessed after a minimum interval of 4 weeks to determine if the dosage should be adjusted toward the maximum daily dose of 80 mg.
  • Dosing is maintained as a chronic, long-term pattern, with mandatory adjustments based on specific co-administered drugs.

Connection to the overall use protocol (2–4 sentences): The instructions establish Delator as a long-term, once-daily oral medication with defined dosage limits from 10 mg to 80 mg. This protocol standardizes the administration by allowing flexibility regarding meal timing and sets a minimum four-week period for dose adjustments, ensuring a methodical approach to maintaining the established concentration pattern. The rules also specify maximum allowable doses when certain other medications are co-administered, explicitly defining procedural constraints for its use.

Recent Clinical Evidence

Evidence for Managing Primary High Cholesterol and Mixed Lipid Disorders

Research into Delator (Atorvastatin) was conducted for the management of high levels of blood fats and primarily involves large-scale clinical trials known as Randomized Controlled Trials (RCTs). These studies were structured to explore how the medicine was observed to relate to key measures of blood lipids, often referred to as surrogate markers. Studies reported measurements of shifts in the blood lipid profile of the observed populations, including measured shifts in LDL-C and Total Cholesterol levels. The evidence contributes to the broader landscape of how to address these metabolic imbalances.

However, the focus of this particular body of evidence is on biomarkers (measurements in the blood) rather than on direct long-term health outcomes. Research provides insight into short-term changes in lipid levels, but it does not determine whether an individual will respond similarly, and trials tracking serious clinical events over many years provide different information.

️ Research on Preventing Heart and Vascular Events

Delator has been extensively evaluated in major clinical trials designed to observe the occurrence of long-term health events. These studies explored the relationship between the medicine and the risk of major cardiovascular and cerebrovascular issues in two key areas.

Primary Prevention in High-Risk Adults

In the context of primary prevention, Delator was studied for its use in patients who had not yet had a heart attack or stroke but had multiple significant risk factors (e.g., high blood pressure, Type 2 Diabetes Mellitus). The studies reported the distribution of major cardiovascular events (MACE) in the groups receiving the medicine and the rates observed in the comparison groups over the study duration. Subgroup findings are uncertain for those at very low overall risk.

Secondary Prevention After a Heart or Vascular Event

The research describes that the use of Delator was observed in relation to the frequency of recurrent heart events, including heart attack and stroke, in previously affected patient cohorts. These findings contribute to the evidence landscape for patients following an acute cardiovascular event.

‍‍‍ Evidence in Specific Patient Groups

Research has explored the use of Delator in specific patient groups, including dedicated clinical trials for children and adolescents (typically over age 10) with inherited conditions like Familial Hypercholesterolemia (FH). In these rare populations, sample sizes were smaller compared to the large prevention trials. The evidence base often relies heavily on changes in surrogate markers, and data for certain groups are still emerging regarding long-term cardiovascular event outcomes.

Key Studies & References

  1. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials (Includes PROVE IT-TIMI 22 and TNT data)
  2. NICE guideline NG238: Cardiovascular disease: risk assessment and reduction, including lipid modification (2023)

Frequently Asked Questions (FAQ)

Common questions about Delator (FAQ)

Q: How long does the effect of Delator last after taking a dose?

Delator is prescribed for chronic, long-term management and is intended to be taken once daily. This dosing schedule indicates that a single dose is designed to maintain the necessary lipid-modifying concentration in the body throughout a 24-hour period.

Q: Is Delator available as a generic medicine?

Yes, the active ingredient in Delator, which is atorvastatin, is widely available as a generic medicine. The availability of the generic version is widely documented.

Q: Does Delator have any known interaction warnings with common over-the-counter medicines?

Official drug labels generally do not list common over-the-counter pain relievers, such as acetaminophen or ibuprofen, as specific drug interactions. Information regarding all medicines, including non-prescription products, is typically discussed with a healthcare provider.

Q: Can Delator affect how my birth control works?

Official product information indicates that Delator may increase the plasma levels of oral contraceptives containing norethindrone and ethinyl estradiol. This effect is a factor for consideration by healthcare providers.

Q: Is it okay to drink coffee or tea while I am taking Delator?

Regulatory documents do not list any interaction or specific restriction related to the consumption of ordinary amounts of coffee or tea while using Delator. The primary restriction regarding beverages is avoiding large amounts of grapefruit juice.

Q: Is it normal to feel tired or dizzy after starting Delator?

Tiredness (fatigue) and dizziness are not listed among the most commonly reported adverse reactions in official prescribing information. However, official warnings note that the statin drug class has been associated with reports of cognitive impairment, such as confusion or memory loss.

Q: Do the side effects of Delator go away after a few weeks?

Official regulatory documents do not specify a timeline for the resolution of common side effects. If a patient experiences serious side effects, particularly signs of muscle pain or liver issues, the medicine is typically discontinued, after which symptoms are typically observed to resolve.

Q: Are there any foods or vitamins I should avoid when using Delator?

It is advised to avoid consuming large quantities (ge 1.2 liters/day) of grapefruit juice, as this can increase the drug's concentration in the body. Additionally, the herbal supplement St. John's Wort is noted to reduce Delator's plasma levels, potentially affecting its efficacy.

Q: Does Delator contain any ingredients that cause allergic reactions?

Delator is strictly contraindicated (officially prohibited) for patients with a known hypersensitivity to the active substance, atorvastatin, or any of the inactive ingredients (excipients) in the tablet. The complete list of excipients is available in the official Prescribing Information.

Q: What does it mean that Delator has a 'Black Box Warning' (if applicable)?

Delator's active ingredient, atorvastatin, is not currently required to carry an FDA 'Black Box Warning' (officially known as a Boxed Warning). It does, however, carry important serious warnings regarding the potential for muscle damage and the absolute contraindication during pregnancy.

Q: Where can I find the official prescribing information for Delator?

Official regulatory information for Delator (atorvastatin) is available on government health websites. These sources include the FDA DailyMed, the NIH MedlinePlus Drug Information database, and similar government-run authority websites.

Q: Is Delator a controlled substance?

No, Delator (atorvastatin) is a prescription medicine but is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: Is Delator known to cause weight gain or weight loss?

Weight gain or weight loss is not listed among the common adverse reactions documented in official regulatory documents. Regulatory documents note that observational studies have sometimes reported small changes in body composition associated with the statin class.

Q: How do I know if Delator is working for me?

The efficacy of Delator is assessed by your healthcare provider primarily through routine blood tests that measure specific blood fat levels, particularly Low-Density Lipoprotein Cholesterol (LDL-C). Dosage adjustments are determined based on these results, typically after a minimum interval of four weeks of treatment.

Q: What should I do if I think I am having a rare side effect from Delator?

Official information indicates that any concerning symptoms or suspected adverse reactions should be communicated to a healthcare provider. Additionally, individuals may report side effects directly to the regulatory authority’s adverse event reporting system, such as the FDA's MedWatch program.

Q: Is it true that Delator is being studied for other medical uses?

Yes, research has explored the relationship between Delator and outcomes in non-cardiovascular areas, such as cognitive function and certain conditions like chronic kidney disease. These are areas of ongoing scientific investigation and are documented in databases like the NIH Clinical Trials database.

Q: Has there been a recall of Delator?

The FDA routinely publishes information regarding drug recalls. If a quality issue leads to a recall of Delator or its generic versions, the information is publicly documented in the FDA Enforcement Reports database.

Q: Does Delator have any known risk for dependence or addiction?

Delator (atorvastatin) is not a controlled substance and is not generally associated with risks of physical dependence or addictive behavior.

Q: Is Delator commonly prescribed in countries outside of the US?

Yes, Delator (atorvastatin) is recognized by international health authorities, including the World Health Organization (WHO), as an essential medicine for cardiovascular conditions. It is therefore prescribed and regulated in many countries globally.

Q: Does Delator affect your sleeping patterns?

Insomnia (difficulty sleeping) is listed as an adverse reaction that occurred in a small percentage of patients (ge 2%) in clinical trials. Sleep disturbances are typically discussed with a healthcare provider.

Q: Can Delator make you feel anxious or depressed?

Anxiety and depression are not consistently listed among the common side effects in official prescribing information. However, official warnings note that the statin drug class has been associated with reports of cognitive impairment, which includes symptoms like memory loss or confusion.

Q: Can I stop taking Delator suddenly, or do I need to taper off?

Official guidance indicates that Delator is intended for long-term chronic management. Discontinuation or changes to the dose are typically determined by a healthcare professional.

Q: Can I take Delator with common pain relievers like Tylenol (acetaminophen)?

Official regulatory documents do not list a specific interaction with common pain relievers like acetaminophen (Tylenol). However, Delator is contraindicated in active liver disease, and since high doses of acetaminophen can also affect the liver, questions about co-administration are typically addressed by a healthcare provider.

Q: How long has Delator been approved and available?

The active ingredient in Delator, atorvastatin, was first approved by the U.S. Food and Drug Administration (FDA) in 1996, and it has been available for prescription use since then.

Q: Can Delator interfere with blood pressure medications?

The metabolism of Delator is highly dependent on the CYP3A4 enzyme, making it susceptible to interactions with other drugs. The label specifically advises that patients taking Delator with certain other drugs, such as Digoxin, should have appropriate monitoring.

Q: What happens if a child accidentally takes Delator?

Official information states that if accidental ingestion or overdose of Delator is suspected, especially by a child or someone for whom the medicine was not prescribed, immediate contact with a poison control center or emergency medical attention is required.

Q: What research is currently happening on Delator?

The NIH Clinical Trials database documents ongoing studies and research involving Delator (atorvastatin) in various therapeutic areas. These studies continue to explore the medicine's potential relationship with different health outcomes.

Q: What does the 'pleiotropic effects' mentioned in the mechanism mean in simple language?

In simple language, pleiotropic effects refer to the medicine's actions that go beyond its main cholesterol-lowering purpose. This includes documented effects like helping to modulate signaling in blood vessel walls, which is associated with reduced inflammation and improved function of the vessels.

Q: Are there any foods or vitamins I should avoid when using Delator? (Consolidated)

The official label notes that consuming large amounts (ge 1.2 liters per day) of grapefruit juice should be avoided as it can increase the drug's concentration. Additionally, the herbal supplement St. John's Wort is noted to reduce Delator’s plasma levels. Any additional dietary questions are typically addressed by a healthcare provider.

Q: Does Delator contain any ingredients that cause allergic reactions? (Consolidated)

Delator is strictly contraindicated (officially prohibited) for patients with a known hypersensitivity to the active substance, atorvastatin, or any of the inactive ingredients (excipients) in the tablet. The complete list of excipients is available in the official Prescribing Information.

Q: How do I know if Delator is working for me? (Consolidated)

Efficacy is assessed by healthcare providers primarily through routine blood tests that measure specific lipid levels, particularly Low-Density Lipoprotein Cholesterol (LDL-C). Dosage adjustments are determined based on these results, typically after a minimum interval of four weeks of treatment.

Q: Why is Delator not recommended for people with specific conditions like active liver disease? (Consolidated)

Delator is contraindicated in patients with active liver disease due to the documented risk of associated abnormalities in liver function tests and, rarely, hepatic failure. It is also contraindicated during pregnancy because of the risk of potential fetal harm. These constraints define the mandatory regulatory boundaries for its use.

Q: Are there any monitoring tests (like blood tests) needed while on Delator? (Consolidated)

Yes, official safety information highlights the need for monitoring the hepatic (liver) system. This involves routine blood tests to check liver function tests (LFTs). The medicine is contraindicated if persistent elevations of liver enzymes are found.

Q: Can men and women use Delator for the same conditions? (Consolidated)

Yes, Delator is approved for use in both men and women for the same lipid-lowering conditions. However, the medicine is strictly contraindicated for women who are pregnant, breastfeeding, or of childbearing potential and not using adequate contraception.

How should Delator be stored and disposed of?

How to Store and Dispose of Delator?

The storage and disposal of Delator (Atorvastatin) tablets must comply strictly with official regulatory requirements to maintain product stability and ensure safety.

Storage Conditions

  • Temperature and Environment: Store the tablets at room temperature, typically below 30 C (86 F). The medication must be protected from excess heat and moisture .
  • Container Rules: Keep Delator in its original container, ensuring it remains tightly closed. Do not use the product past the expiration date printed on the packaging.
  • Child Safety: The medication must always be kept out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets must be done in accordance with local requirements. The preferred method is using a drug take-back program. If a program is unavailable, follow household disposal procedures as advised by regulators, which typically involves mixing the tablets with an unappealing substance and placing them in a sealed container for trash. Do not flush the medication down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Delator found in:

A-Z Index: